• COVID-19 Resources
  • About
  • Subscribe
  • Promotions
  • Advertise
  • Contact Us
  • May 9, 2025

Milwaukee Courier Weekly Newspaper

"THE NEWSPAPER YOU CAN TRUST SINCE 1964"

  • News
  • Editorials
  • Education
  • Urban Business
  • Health
  • Religion
  • Upcoming Events
  • Classifieds
EXCEPT WHERE INDICATED, THE OPINIONS EXPRESSED ON THIS PAGE ARE NOT NECESSARILY THOSE OF THE MILWAUKEE COURIER

Share:

  • Click to share on Facebook (Opens in new window) Facebook
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

Antibiotic Resistance Worsens COVID-19 Outcomes

April 18, 2020

By Kenneth E. Thorpe

Kenneth E. Thorpe

Hospitals across the globe are overwhelmed with coronavirus patients. Many of those patients ultimately develop viral pneumonia, one of the most common symptoms.

But a subset of patients must fight another, more terrifying enemy: drug-resistant bacteria, or “superbugs.”

These secondary bacterial infections are largely immune to our current antibiotics arsenal. And as a result, patients who might have survived if we had more effective treatments are dying instead. If lawmakers don’t learn from this quickly — and jumpstart antibiotics development — we’ll be woefully unprepared when the next pandemic strikes.

The outbreak of COVID-19 has brought the threat of antibiotic resistance front and center. But it’s far from a new public health challenge.

Every time a patient takes any antibiotics to treat an infection, some bacteria survive. These surviving strains can multiply and evolve into deadly, treatment-resistant superbugs. Last year, superbugs infected one American every 11 seconds and killed one every 15 minutes.

Today, amid the COVID-19 crisis, superbugs pose an exponentially greater threat. In one Lancet study of 41 hospitalized coronavirus patients, 10% developed secondary infections.

A different Lancet study of 99 COVID-19 patients with secondary infections identified five types of bacteria in their systems, one of which — A baumannii — was antibiotic-resistant. This particular superbug can cause septic shock, resulting in severe organ damage and, in some cases, death.

Unfortunately, the widespread use of antibiotics has an unintended effect – it inevitably fuels the evolution of superbugs. Every patient in the first Lancet study, even those without secondary infections, received antibiotics.

Solving the challenge of antibiotic resistance requires a two-part solution. First, we need to make sure patients are receiving the right antibiotics for their particular infections — but only when appropriate. Second, we need to develop new, more potent antibiotics.

Drug development is a challenging, expensive venture. On average, innovators can expect to spend 10 to 15 years and up to $2.6 billion to create just one new medicine. Companies accept these risks because if they succeed, there’s a good chance they’ll be able to sell enough of their treatments to recoup their research dollars.

This sales model works for most types of drugs, but not for antibiotics. Unlike treatments for many chronic diseases, antibiotics are intended for extremely selective use. Such restrictions make sense, medically speaking — but they make it difficult for antibiotics developers to earn back their investments.

It is time lawmakers fixed the broken antibiotic market and catalyzed the creation — and responsible use — of new treatments to save lives.

Lawmakers could consider policies that increase reimbursements for hospitals that appropriately administer novel antibiotics.

In turn, demand would likely increase and it would become viable for firms to develop antibiotics.

Governments could also offer “market entry rewards” to companies working to produce novel antibiotics. This would provide companies the opportunity to recoup research and development capital. In turn, this would incentivize more investment in antibiotic research projects.

COVID-19 offers a stark warning to every lawmaker and health policymaker. Unless we get serious about fighting antimicrobial resistance, we’ll remain woefully unprepared in future pandemics.

Kenneth E. Thorpe is a professor of health policy at Emory University and chairman of the Partnership to Fight Chronic Disease.

Share:

  • Click to share on Facebook (Opens in new window) Facebook
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

Popular Interests In This Article: Antibiotic Resistance, COVID-19, Kenneth E. Thorpe

Read More - Related Articles

  • Pandemic brings telehealth boom to rural Wisconsin, but barriers linger
  • The Most Transmissible Strain of the Coronavirus in the Country is Also now the Most Prevalent. Here’s What you Need to Know
  • Black Doctor Debunks COVID-19 Myths on TikTok to Reach Black Americans
  • COVID, the Flu, RSV, Respiratory Illnesses Abound
  • Biden Administration Announces Winter COVID-19 Preparedness Plan
Become Our Fan On Facebook
Find Us On Facebook


Follow Us On X
Follow Us On X

Editorials

Lakeshia Myers
Michelle Bryant
Dr. Kweku Akyirefi Amoasi formerly known as Dr. Ramel Smith

Journalists

Karen Stokes

Topics

Health Care & Wellness
Climate Change
Upcoming Events
Obituaries
Milwaukee NAACP

Politicians

David Crowley
Cavalier Johnson
Marcelia Nicholson
Governor Tony Evers
President Joe Biden
Vice President Kamala Harris
Former President Barack Obama
Gwen Moore
Milele A. Coggs
Spencer Coggs

Classifieds

Job Openings
Bid Requests
Req Proposals
Req Quotations
Apts For Rent

Contact Us

Milwaukee Courier
2003 W. Capitol Dr.
Milwaukee, WI 53206
Ph: 414.449.4860
Fax: 414.906.5383

Copyright © 2025 · Courier Communications | View Privacy Policy | Site built and maintained by Farrell Marketing Technology LLC
We use third-party advertising companies to serve ads when you visit our website. These companies may use information (not including your name, address, email address, or telephone number) about your visits to this and other websites in order to provide advertisements about goods and services of interest to you. If you would like more information about this practice and to know your choices about not having this information used by these companies, click here.